Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cholera | 7 | 2018 | 189 | 2.28 | Why? |
| Infectious Disease Incubation Period | 4 | 2020 | 1033 | 0.97 | Why? |
| Diphtheria | 1 | 2020 | 74 | 0.79 | Why? |
| Vibrio cholerae | 1 | 2018 | 44 | 0.74 | Why? |
| School Teachers | 1 | 2021 | 345 | 0.65 | Why? |
| Models, Theoretical | 6 | 2021 | 6659 | 0.54 | Why? |
| Measles Vaccine | 1 | 2017 | 301 | 0.53 | Why? |
| Cholera Vaccines | 3 | 2018 | 56 | 0.51 | Why? |
| Demography | 2 | 2018 | 1660 | 0.51 | Why? |
| Disease Outbreaks | 12 | 2021 | 27595 | 0.51 | Why? |
| Measles | 2 | 2018 | 608 | 0.50 | Why? |
| Vaccination | 4 | 2021 | 19050 | 0.41 | Why? |
| Models, Statistical | 4 | 2021 | 5312 | 0.37 | Why? |
| Public Policy | 1 | 2021 | 1894 | 0.36 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.33 | Why? |
| Schools | 2 | 2021 | 4187 | 0.31 | Why? |
| Family Characteristics | 3 | 2021 | 2551 | 0.31 | Why? |
| Communicable Diseases | 2 | 2018 | 2148 | 0.29 | Why? |
| Contact Tracing | 3 | 2021 | 8448 | 0.27 | Why? |
| Epidemics | 4 | 2021 | 6407 | 0.27 | Why? |
| Community-Acquired Infections | 2 | 2020 | 2328 | 0.26 | Why? |
| Decision Support Techniques | 1 | 2010 | 903 | 0.24 | Why? |
| Communicable Diseases, Emerging | 1 | 2017 | 2523 | 0.24 | Why? |
| Students | 1 | 2021 | 5255 | 0.24 | Why? |
| Geography | 3 | 2018 | 1801 | 0.24 | Why? |
| Population Density | 2 | 2018 | 694 | 0.23 | Why? |
| SARS Virus | 2 | 2021 | 13021 | 0.21 | Why? |
| Bacterial Vaccines | 1 | 2021 | 139 | 0.20 | Why? |
| Disease Transmission, Infectious | 6 | 2021 | 9044 | 0.20 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.20 | Why? |
| Chad | 1 | 2018 | 25 | 0.19 | Why? |
| Respiratory Tract Infections | 2 | 2010 | 6817 | 0.18 | Why? |
| Rubella virus | 1 | 2018 | 46 | 0.18 | Why? |
| Mupirocin | 1 | 2017 | 22 | 0.18 | Why? |
| El Nino-Southern Oscillation | 1 | 2017 | 7 | 0.18 | Why? |
| Africa | 2 | 2017 | 2986 | 0.17 | Why? |
| Circumcision, Male | 1 | 2017 | 57 | 0.17 | Why? |
| Humans | 48 | 2021 | 930598 | 0.16 | Why? |
| Africa South of the Sahara | 2 | 2021 | 1335 | 0.16 | Why? |
| Viruses | 1 | 2010 | 2238 | 0.16 | Why? |
| Rubella | 1 | 2018 | 127 | 0.16 | Why? |
| Democratic Republic of the Congo | 1 | 2018 | 500 | 0.16 | Why? |
| Measles virus | 1 | 2018 | 194 | 0.16 | Why? |
| Hemorrhagic Fever, Ebola | 2 | 2018 | 1475 | 0.16 | Why? |
| Public Health | 3 | 2021 | 16359 | 0.16 | Why? |
| Severe Dengue | 1 | 2018 | 135 | 0.15 | Why? |
| Risk | 5 | 2021 | 5288 | 0.15 | Why? |
| Congenital Abnormalities | 1 | 2017 | 170 | 0.15 | Why? |
| Child, Preschool | 8 | 2021 | 36283 | 0.15 | Why? |
| Markov Chains | 1 | 2018 | 502 | 0.15 | Why? |
| Bacterial Infections | 2 | 2021 | 2229 | 0.15 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2020 | 8843 | 0.14 | Why? |
| Dengue | 2 | 2018 | 1565 | 0.14 | Why? |
| Child | 12 | 2021 | 70012 | 0.14 | Why? |
| Sanitation | 1 | 2018 | 403 | 0.13 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.13 | Why? |
| Coronavirus OC43, Human | 1 | 2021 | 1157 | 0.13 | Why? |
| Bayes Theorem | 2 | 2020 | 3237 | 0.13 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.13 | Why? |
| Infant, Newborn, Diseases | 1 | 2017 | 394 | 0.12 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.12 | Why? |
| Cross Infection | 2 | 2017 | 8675 | 0.12 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2007 | 2984 | 0.12 | Why? |
| Virus Diseases | 1 | 2010 | 3779 | 0.12 | Why? |
| Hepatitis E | 1 | 2017 | 319 | 0.12 | Why? |
| Infant | 7 | 2020 | 30274 | 0.12 | Why? |
| Disease Eradication | 1 | 2018 | 581 | 0.11 | Why? |
| Terminology as Topic | 1 | 2017 | 546 | 0.11 | Why? |
| Adolescent | 12 | 2021 | 86841 | 0.11 | Why? |
| Asymptomatic Infections | 3 | 2021 | 7218 | 0.11 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.11 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.11 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.10 | Why? |
| Epidemiological Monitoring | 3 | 2018 | 3493 | 0.10 | Why? |
| Masks | 3 | 2021 | 8528 | 0.10 | Why? |
| Incidence | 5 | 2018 | 25622 | 0.10 | Why? |
| South Sudan | 2 | 2021 | 107 | 0.10 | Why? |
| Dengue Virus | 1 | 2017 | 910 | 0.10 | Why? |
| Forecasting | 2 | 2021 | 4492 | 0.09 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.09 | Why? |
| Public Health Practice | 1 | 2017 | 945 | 0.09 | Why? |
| Disease Susceptibility | 2 | 2021 | 4002 | 0.09 | Why? |
| Decision Trees | 1 | 2010 | 441 | 0.09 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.09 | Why? |
| Liberia | 2 | 2018 | 108 | 0.09 | Why? |
| Urban Population | 1 | 2018 | 2000 | 0.09 | Why? |
| Feces | 1 | 2021 | 4235 | 0.09 | Why? |
| Staphylococcal Infections | 1 | 2017 | 1099 | 0.09 | Why? |
| Mass Vaccination | 1 | 2018 | 1101 | 0.08 | Why? |
| Refugees | 1 | 2017 | 809 | 0.08 | Why? |
| Seroepidemiologic Studies | 5 | 2021 | 10017 | 0.08 | Why? |
| Models, Biological | 2 | 2021 | 4907 | 0.08 | Why? |
| Probability | 1 | 2010 | 923 | 0.08 | Why? |
| Data Interpretation, Statistical | 1 | 2010 | 657 | 0.08 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.07 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.07 | Why? |
| United States | 3 | 2021 | 46150 | 0.07 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.07 | Why? |
| Quarantine | 3 | 2021 | 18418 | 0.07 | Why? |
| Saudi Arabia | 1 | 2016 | 4423 | 0.07 | Why? |
| Zika Virus | 1 | 2017 | 1924 | 0.07 | Why? |
| Guillain-Barre Syndrome | 1 | 2017 | 1495 | 0.07 | Why? |
| Phylogeny | 2 | 2021 | 13341 | 0.07 | Why? |
| Software | 2 | 2021 | 2501 | 0.07 | Why? |
| Young Adult | 9 | 2021 | 93724 | 0.07 | Why? |
| Zika Virus Infection | 1 | 2017 | 1920 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.06 | Why? |
| Adult | 11 | 2021 | 244371 | 0.06 | Why? |
| Health Services Needs and Demand | 1 | 2018 | 3419 | 0.06 | Why? |
| Thailand | 2 | 2018 | 1155 | 0.06 | Why? |
| Influenza, Human | 1 | 2007 | 10779 | 0.06 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.06 | Why? |
| Natural History | 1 | 2021 | 40 | 0.06 | Why? |
| Propensity Score | 1 | 2010 | 2690 | 0.06 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.05 | Why? |
| Health Policy | 1 | 2021 | 6242 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.05 | Why? |
| Baltimore | 1 | 2021 | 220 | 0.05 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.05 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.05 | Why? |
| Utah | 1 | 2021 | 425 | 0.05 | Why? |
| District of Columbia | 1 | 2021 | 343 | 0.05 | Why? |
| Computer Simulation | 3 | 2021 | 4982 | 0.05 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.05 | Why? |
| Leisure Activities | 1 | 2021 | 221 | 0.05 | Why? |
| Basic Reproduction Number | 2 | 2021 | 2676 | 0.05 | Why? |
| Genome, Viral | 1 | 2021 | 13157 | 0.05 | Why? |
| Immunoglobulin Isotypes | 1 | 2020 | 308 | 0.05 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2018 | 191 | 0.04 | Why? |
| Rain | 1 | 2018 | 108 | 0.04 | Why? |
| Prevalence | 2 | 2017 | 25773 | 0.04 | Why? |
| Tanzania | 1 | 2018 | 294 | 0.04 | Why? |
| Boston | 1 | 2021 | 929 | 0.04 | Why? |
| Malawi | 1 | 2018 | 287 | 0.04 | Why? |
| Male | 11 | 2021 | 367725 | 0.04 | Why? |
| Population Dynamics | 1 | 2021 | 378 | 0.04 | Why? |
| Female | 11 | 2021 | 380317 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Hepatitis Antibodies | 1 | 2017 | 100 | 0.04 | Why? |
| Dengue Vaccines | 1 | 2018 | 123 | 0.04 | Why? |
| Poisson Distribution | 1 | 2017 | 348 | 0.04 | Why? |
| Americas | 1 | 2017 | 418 | 0.04 | Why? |
| Massachusetts | 1 | 2021 | 1279 | 0.04 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.04 | Why? |
| Aged | 7 | 2021 | 215776 | 0.04 | Why? |
| China | 2 | 2020 | 50654 | 0.04 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.04 | Why? |
| Seasons | 2 | 2018 | 4071 | 0.04 | Why? |
| Case Management | 1 | 2018 | 285 | 0.04 | Why? |
| Logistic Models | 1 | 2010 | 9089 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.04 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.04 | Why? |
| Infection Control | 2 | 2021 | 23131 | 0.03 | Why? |
| Water Purification | 1 | 2018 | 285 | 0.03 | Why? |
| United Nations | 1 | 2017 | 367 | 0.03 | Why? |
| Mosquito Vectors | 1 | 2017 | 351 | 0.03 | Why? |
| Uganda | 1 | 2017 | 1057 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.03 | Why? |
| Hepatitis E virus | 1 | 2017 | 306 | 0.03 | Why? |
| Switzerland | 1 | 2021 | 2738 | 0.03 | Why? |
| Culture | 1 | 2017 | 370 | 0.03 | Why? |
| Health Plan Implementation | 1 | 2018 | 571 | 0.03 | Why? |
| Base Sequence | 1 | 2021 | 3581 | 0.03 | Why? |
| Administration, Intranasal | 1 | 2017 | 1132 | 0.03 | Why? |
| Length of Stay | 1 | 2010 | 11042 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Health Services Research | 1 | 2017 | 756 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2017 | 1182 | 0.03 | Why? |
| Animals | 2 | 2017 | 78931 | 0.03 | Why? |
| Community Participation | 1 | 2017 | 605 | 0.03 | Why? |
| Vaccines, Inactivated | 1 | 2017 | 1562 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Cost of Illness | 1 | 2020 | 1903 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| Genomics | 1 | 2021 | 3118 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.02 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.02 | Why? |
| Outpatients | 1 | 2021 | 3417 | 0.02 | Why? |
| Sequence Analysis, RNA | 1 | 2017 | 2290 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| Disease Reservoirs | 1 | 2016 | 1672 | 0.02 | Why? |
| Time Factors | 1 | 2010 | 31397 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.02 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| France | 1 | 2020 | 12074 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.02 | Why? |
| International Cooperation | 1 | 2017 | 3436 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.02 | Why? |
| Zoonoses | 1 | 2016 | 3034 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Population Surveillance | 1 | 2018 | 4967 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2017 | 9091 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.01 | Why? |
| Artificial Intelligence | 1 | 2010 | 3543 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Algorithms | 1 | 2010 | 7346 | 0.01 | Why? |
Lessler's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(205)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(293)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_